Feb 23 2024International Vaccine Institute SK bioscience and the International Vaccine Institute announced today that the typhoid conjugate vaccine developed by SK bioscience with technology transfer from IVI has achieved the World Health Organization prequalification , which paves the way for public procurement of the vaccine by UN organizations and gives a boost to the global TCV supply.
The new vaccine SKYTyphoid™, which has received the WHO's seal of approval this time, is a typhoid conjugate vaccine developed jointly by SK bioscience and IVI following IVI's technology transfer with funding support from the Bill & Melinda Gates Foundation. SK bioscience was the manufacturing partner and IVI led clinical trials conducted in the Philippines and Nepal.
Based on clinical results, SKYTyphoid™ obtained a licensure for export from the Korean Ministry of Food and Drug Safety in 2022. A Phase 3 clinical trial conducted by SK bioscience and IVI in Nepal on 2,160 healthy individuals aged 6 months to 45 years had confirmed the excellent immunogenicity and safety of the vaccine.
The WHO licensure of SK bioscience's TCV represents the successful conclusion of a global public-private partnership to bring a novel vaccine crucial to global public health to market. SKYTyphoid™ will diversify and expand the supply of TVCs and help improve vaccine access in the endemic countries. With SK's commitment to make the vaccine for global public health at a competitive price, SKYTyphoid™ will play an important role in typhoid prevention globally.